The FDA has issued two approvals involving the use of Rebetol capsules (ribavirin), Intron A injection (interferon alfa-2b) and PEG-Intron injection (peginterferon alfa-2b) (all Schering Corp, Kenilworth, NJ) to treat patients with chronic hepatitis C.
Rebetol capsules and Intron A had been approved as a single-package combination therapy for treatment of patients with chronic hepatitis C infection who have not had interferon therapy or who have relapsed following such therapy. The new approval provides for the distribution of Rebetol without Intron A, thereby giving prescribers flexibility in adopting individualized ribavirin- and interferon-based therapies.
Schwetz BA. Treatment for Hepatitis C. JAMA. 2001;286(10):1166. doi:10.1001/jama.286.10.1166-JFD10008-2-1